Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

By

"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.

Valbenazine Assessed for Long-Term Treatment of Tardive Dyskinesia

Valbenazine Assessed for Long-Term Treatment of Tardive Dyskinesia

By

Ingrezza was well-tolerated in patients with tardive dyskinesia.

New Dose Approved for Tardive Dyskinesia Drug Ingrezza

New Dose Approved for Tardive Dyskinesia Drug Ingrezza

By

Ingrezza is a vesicular monoamine transporter 2 inhibitor, now available in an 80mg capsule.

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

By

Incidence of neuroleptic malignant syndrome, akathisia, and parkinsonism was higher in the ID group.

Austedo Wins Second Indication for Tardive Dyskinesia

Austedo Wins Second Indication for Tardive Dyskinesia

By

Austedo was previously approved for the treatment of chorea in Huntington's disease.

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

By

The main challenge is to determine when treating tardive dyskinesia with any pharmacological agent would provide a net benefit.

Treating Tardive Dyskinesia Without Disrupting Psychiatric Treatment

Treating Tardive Dyskinesia Without Disrupting Psychiatric Treatment

By

Joohi Jimenez-Shahed, MD, discusses her research on the use of deutetrabenazine for the treatment of tardive dyskinesia in patients taking concomitant antipsychotics or neuroleptics. Scroll below the video for the full transcript.

Tardive Dyskinesia Treatment Approved by FDA

Tardive Dyskinesia Treatment Approved by FDA

By

Valbenazine is the first drug approved for the treatment of tardive dyskinesia, an adverse effect associated with the use of some antipsychotic medications.

Sign Up for Free e-newsletters



CME Focus